Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Mallinckrodt
Boehringer Ingelheim
Cantor Fitzgerald
Cipla
Chinese Patent Office

Generated: September 17, 2019

DrugPatentWatch Database Preview

Patent: 10,240,207

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,240,207
Title:Cancer treatment with c-met antagonists and correlation of the latter with HGF expression
Abstract: The present invention concerns cancer biomarkers. In particular, the invention concerns HGF as a biomarker for patient selection and patient prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.
Inventor(s): Yu; Wei (South San Francisco, CA), Shames; David (South San Francisco, CA), Koeppen; Hartmut (South San Francisco, CA), Phan; See (South San Francisco, CA), Rost; Sandra (South San Francisco, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Application Number:15/272,283
Patent Claims:see list of patent claims

Details for Patent 10,240,207

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26 ➤ Sign Up Genentech, Inc. (South San Francisco, CA) 2034-03-24 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26 ➤ Sign Up Genentech, Inc. (South San Francisco, CA) 2034-03-24 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Queensland Health
US Army
Citi
US Department of Justice
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.